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Beverley M Essue1*, Germaine Wong2, Jeremy Chapman3, Qiang Li1 and Stephen Jan1Abstract
Background: Chronic kidney disease (CKD) poses a financial burden on patients and their households. This
descriptive study measures the prevalence of economic hardship and out-of-pocket costs in an Australian CKD
population.
Methods: A cross-sectional study of patients receiving care for CKD (stage III-V) in Western Sydney, Australia using a
structured questionnaire. Data collection occurred between November 2010 and April 2011. Multivariate analyses
assessed the relationships between economic hardship and individual, household and health system characteristics.
Results: The study included 247 prevalent CKD patients. A mean of AUD$907 per three months was paid
out-of-pocket resulting in 71% (n=153) of participants experiencing financial catastrophe (out-of-pocket costs
exceeding 10% of household income). Fifty-seven percent (n=140) of households reported economic hardship. The
adjusted risk factors that decreased the likelihood of hardship included: home ownership (OR: 0.32, 95% CI: 0.14-0.71),
access to financial resources (OR: 0.24, 95% CI: 0.11-0.50) and quality of life (OR: 0.12, 95% CI: 0.02-0.56). The factors that
increased the likelihood of hardship included if income was negatively impacted by CKD (OR: 4.80, 95% CI: 2.17-10.62)
and concessional status (i.e. receiving government support) (OR: 3.09, 95% CI: 1.38-6.91). Out-of-pocket costs and
financial catastrophe were not found to be significantly associated with hardship in this analysis.
Conclusions: This study describes the poorer economic circumstances of households affected by CKD and reinforces
the inter-relationships between chronic illness, economic well-being and quality of life for this patient population.
Keywords: Chronic kidney disease, Economic hardship, Out-of-pocket costs, AustraliaBackground
Chronic kidney disease (CKD) management imposes a
substantial financial burden on both health systems and
on patients and their households. In 2004-05 the total
health expenditure for CKD exceeded AUD$898.7 mil-
lion in Australia - 1.7% of the health care budget [1] and
similar levels of expenditure are reported for other
OECD countries [2,3]. Against this is a background of
increasing health expenditure in the form of out-of-
pocket payments [4]. Supportive care provided to
Australian patients starts at around AUD$50,000 per
annum for dialysis care [5] and while out-of-pocket
expenses are only a small proportion of the total cost of* Correspondence: beverley.essue@sydney.edu.au
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reproduction in any medium, provided the orcare, their impact can be severe. For example, in a 2006
study of Australian patients receiving dialysis care in
Victoria either in a community location or at home,
patients paid an average of AUD$1,237 and AUD$480
out-of pocket annually respectively [6]. These expenses
occur at a time when there are interruptions to paid em-
ployment and earlier than expected departures from the
workforce for the patient and often a family carer [7].
Most studies that estimate out-of-pocket costs only
quantify direct costs for treatment and medications [6],
overlooking the often substantial costs that are asso-
ciated with self-management, including: medically
related transport, home-care assistance, illness-related
home modifications (e.g. for home dialysis set-up) and
assistive devices. In Australia, the direct costs of medical
care are at least partly covered by health insurance ortd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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below). However, self-management expenses are usually
paid by patients so previous studies likely under-estimate
the true out-of-pocket costs associated with CKD. Fur-
thermore, few studies have quantified the burden more
broadly to patients and households in terms of economic
hardship and financial distress. In other chronic disease
patient populations high rates of economic hardship have
been reported based on a reported inability to maintain
important living expenses [8-10], medical care costs [11]
and with this, compromised adherence to medical care
and quality of life [1,12]. As CKD disproportionately
affects lower socioeconomically disadvantaged individuals
it can reasonably be expected that this patient population
is also at risk of economic hardship.
An overview of the Australian health and social
welfare systems [4]
The Australian government operates a national health
insurance scheme known as Medicare, which subsidises
non-public outpatient medical treatment and
medications. Medicare rebates a portion of the costs of
medical, nursing and allied health services on a fee-for-
service basis. Some medical services can be bulk-billed,
meaning that the provider charges the same amount as
the Medicare rebate, resulting in no out-of-pocket
expense. Prescription pharmaceuticals that are approved
and listed on the Pharmaceutical Benefit Scheme are
also subsidised and individuals are responsible for
contributing a co-payment. The Australian government
administers safety net programs to cap individual out-
of-pocket costs for medical services and prescription
pharmaceuticals. In addition, the State and Territory
governments operate a public hospital system, which
provides inpatient services free of charge. They also
provide some support for treatment and management
aids and services (e.g. transport and appliances) and this
is usually means tested. Private health insurance is
available for supplementary services such as private
hospital treatment, dental services and allied health
services and is heavily supported by government
subsidies and tax rebates.
The Australian government also operates a separate
national welfare system known as Centrelink. Income
support through Centrelink is available for age
pensions based on means and asset tests and disability
pensions based on functional capacity. Pensioners,
also referred to as concessional patients, are entitled
to receive a number of concessions and subsidies for
living, medical and pharmaceutical expenses and are
more likely to receive bulk-billed services.
This descriptive study had the following two aims: 1) to
quantify the economic burden among patients withCKD and identify factors that are associated with
economic hardship; and 2) to quantify out-of-pocket
spending associated with CKD care.
Methods
Setting and participants
We recruited English-speaking individuals currently re-
ceiving care for CKD III-V in Western Sydney, Australia.
An opt-in invitation and a study questionnaire were
mailed to a cross-section of individuals, identified by
convenience sampling by clinic staff, across the
spectrum of illness, including those receiving renal re-
placement therapy. Individuals either self-administered
the questionnaire or completed it with the assistance of
a researcher over the phone. The questionnaire was re-
sent to all non-respondents six weeks after the initial
mailing and the remaining non-respondents at 10 weeks
were re-contacted by telephone with a further reminder.
In addition, all English-speaking individuals receiving
dialysis therapy in the three community-based dialysis
facilities that served the Western Sydney area were also
invited to participate. Individuals who had already com-
pleted the questionnaire by post were not invited to par-
ticipate again. Clinical staff at each centre provided
information about the study to those who were inter-
ested and individuals either self-completed the question-
naire or completed it with the assistance of a researcher.
The return of a completed questionnaire by post was
understood to imply consent to participate in the study.
Participants who completed the questionnaire in person
with the assistance of a researcher provided written
informed consent. This study was approved by the
Human Research Ethics Committees of the Sydney West
Area Health Service (HREC 2008/5/4.14 (2794)) and the
University of the Sydney (12623).
Study questionnaire
The questionnaire was developed based on the authors’
previous work [9,13,14] and included questions that
were drawn from existing validated tools [15-18] and
covered the following domains: demographics; medical
history; quality of life; self-reported chronic illness and
disability, household economic circumstances and social
connection (i.e. the number of social contacts). The
questionnaire domains and variables are described in
Additional file 1: Table S1.
The economic burden of CKD
The economic burden of CKD was measured using the
following outcomes: 1) household economic hardship
(hardship hereafter) and 2) out-of-pocket costs on med-
ical and health-related expenses.
Hardship was measured using a series of questions
about financial stress (e.g. failure to pay basic living and
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previous 12 months. Dissaving behaviour is any action
where spending is greater than income thereby reducing
already accumulated savings or leading to borrowing to
finance the expenditure [17]. Hardship was constructed
as a dichotomous variable where a reported inability to
make any of the payments posed or the use of a dissav-
ing action was classed as a case of hardship.
Participants were asked about their out-of-pocket costs
in the past three months for the following expenses: pre-
scription and non-prescription medications; medical
appointments; hospitalisations; medical tests; medically-
related transportation (including: ambulance; public, pri-
vate and subsidised transport); home and self-care assist-
ance; medical equipment and supplies; illness-related
home modifications and special food required for an
illness-related diet. The burden of out-of-pocket costs was
calculated as total out-of-pocket expenditure in the past
three months as a proportion of the household’s equiva-
lised income for the same quarter. Equivalised household
income (income hereafter), was calculated using the
Organisation for Economic Cooperation and Develop-
ment’s equivalence scales [19], which make adjustments to
actual income to account for households of different size
and composition. An out-of-pocket burden greater than
10 percent was defined as financial catastrophe [20].
Statistical analysis
We conducted descriptive analyses of frequencies for each
component of hardship and means, medians and distribu-
tions for out-of-pocket spending. Bivariate analyses, using
the chi-square test and the independent t-test, were used to
compare participants with and without hardship for cat-
egorical and continuous variables respectively. Given the
positive skew of the cost data, the Mann-Whitney U and
Kruskal-Wallis one-way ANOVA were used to evaluate dif-
ferences in median spending in the sample, by stage of ill-
ness and by hardship status. Logistic regression was used to
identify the factors that were associated with hardship, be-
ginning with a saturated model that included all potential
explanatory variables that were associated with hardship at
the level of P <0.25 in the univariate analysis as well as the
variable for age. Variables were assessed individually for sig-
nificant contribution to the overall model (P< 0.05) manu-
ally. Effect modification was checked between variables in
the model to identify interactions that were significant at
the level of P<0.01. The Hosmer and Lemeshow goodness-
of-fit test was used to check the fit of the final model. Data
analysis was conducted using SAS version 9.2.
Results
Recruitment and participant characteristics
This study achieved a participation rate of 63%, n=247
(Figure 1). The sample included 23 patients with CKDwho were not yet receiving dialysis (pre-dialysis partici-
pants hereafter), 199 participants receiving dialysis
therapy, dialysing either at home (n=70) or in a commu-
nity centre (n=129) and 25 transplant recipients. The
mean age of participants was 59 (SD:15) years, 43% were
female (n=107) and 65% (n=161) were married or living
with a partner (Table 1). Participants reported an average
of three comorbid conditions and hypertension (69%,
n=170) and diabetes (40%, n=99) were most commonly
reported. The average quality of life score (score between
zero and one – a higher score signifies better quality of
life) was 0.64 (SD: 0.25) and this did not differ significantly
by the stage of CKD. Most participants were out of the
workforce, either retired (n=121) or unemployed (n=76)
and 74% (n=183) reported receiving some form of govern-
ment support (e.g. income assistance, concessions or sub-
sidies for living expenses) in the past year. In addition,
37% (n=91) of participants had private health insurance.
Compared to the treated incident renal population in
Australia, our sample had a significantly higher propor-
tion of working-aged adults (45-64 years) (Additional
file 1: Table S2). The study population may also have
been less sick, given the significantly lower prevalence of
co-morbid lung disease and cardiovascular disease, and
the significantly higher quality of life among dialysis
patients. Participants also reported a higher socioeco-
nomic status, signified by higher proportions of home
ownership, health insurance coverage and individuals in
paid work. However, when compared with the Australian
population as a whole, our population of prevalent CKD
patients was generally less well off, with more people
out of the workforce and lower health insurance cover-
age, which is consistent with the characteristics of
chronically ill patients in Australia [20].
Hardship associated with CKD
Fifty-seven percent of participants (n=140) had hardship
(Figure 2). Paying for utility bills posed the greatest bur-
den with 28% (n=69) of participants reporting an inabil-
ity to pay a gas, electricity or telephone bill in the
previous 12 months. Nineteen percent (n=46) were un-
able to pay for medications, 14% (n=35) were unable to
pay co-payments to attend medical appointments and
18% (n=44) reported missing medical appointments or
failed to fill prescriptions in the previous year because
they were short of money. Drawing on long-term savings
was the main dissaving action reported (31%, n=76).
From the multivariable model, after adjusting for age,
participants who owned their home (OR: 0.32, 95% CI:
0.14-0.71), had access to financial resources (OR: 0.24,
CI: 0.11-0.50) and had higher quality of life (OR: 0.12, CI:
0.02-0.56) were less likely to have hardship (Table 2). The
number of social encounters per week also had a non-
significant protective effect. The factors that increased the
Figure 1 Flow of participants into the study.
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come was negatively impacted by CKD (e.g. due to early
departure from the workforce or change in employment
circumstances) (OR: 4.80, CI: 2.17-10.62) and concession
status (OR: 3.09, CI: 1.38-6.91). There was no evidence of
effect modification among the variables and the final
model fit the data well (χHM
2 =4.48, p=0.81).Relationship between out-of-pocket costs and hardship
Similar mean out-of-pocket costs were reported for pre-
dialysis, dialysis and transplant care – AU$961 (SD:AU
$1211), AU$927 (SD:AU$1089) and AU$831 (SD:AU
$803) respectively per quarter (AU$1=US$1=EU€0.73=BG
£0.62; January 2011). At this level of spending, 153 (71%)
participants experienced financial catastrophe. In terms of
the sources of out-of-pocket costs, pre-dialysis partici-
pants spent the most out-of-pocket in the previous three
months on medical care ( ―x =AU$527, SD:AU$1228)
(Figure 3). Median spending in this category was signifi-
cantly higher than that of dialysis and transplant partici-
pants (χ2= 22.33, p<0.0001). Participants receiving dialysis
care and those with a transplant both spent the most on
management and supportive care in their home, AU$538
(SD:AU$900) and AU$495 (SD:AU$663) respectively,
which included: home and self-care assistance; medical
equipment; illness-related home modifications and illness-
specific diets. Large out-of-pocket costs on illness-
related home modifications (>AU$1000) were reported
by a small number of transplant (n=2) and home dia-
lysis (n=5) participants. When these cases were
removed from the analysis, mean spending in this cat-
egory was reduced to AU$374 (SD:AU$449) for those
on dialysis and AU$250 (SD:AUD$156) for transplantrecipients. Finally, participants receiving dialysis also
reported significantly higher out-of-pocket spending
on medically related transport ―x =AU$312, SD:AU
$298; χ2=6.03, p=0.05).
The multivariable logistic regression model described
above did not identify out-of-pocket costs as a signifi-
cant determinant of hardship. Table 3 summarises the
out-of-pocket costs for each medical and health-related
expense category. We found similar levels of spending
across all cost categories between those with and with-
out hardship, indicating that those with hardship, despite
having less financial resources available to them, main-
tained levels of expenditure comparable to those not ex-
periencing hardship.Discussion
This is the first study to comprehensively measure in
patients with CKD in Australia the total out-of-pocket
costs and the extent of hardship that are associated with
the care of CKD. The prevalence of hardship reported in
this study is lower than that found for other chronically
ill patient populations in the same region [9]. However,
it lies well above the levels that tend to be seen in the
Australian population [17] and is consistent with rates
of hardship in other chronically ill populations inter-
nationally [10,21]. In addition, the burden of out-of-
pocket costs found in this study, a mean of AUD$907 in
the previous three months is far greater than estimates
found in other studies [6], reinforcing wider concerns
about the extent to which the Australian health care sys-
tem relies on individual contributions to fund health
care. Individual spending on health care in Australia is
high by international, high-income country standards. In








Mean age (years) 59 (SD:15) 56 (SD:14) 62 (SD:15) 0.001
Gender (Females) 107/246 (43%) 59 (42%) 48 (45%) 0.71
Culturally and linguistically diverse 85/246 (35%) 54 (39%) 31 (29%) 0.13
Married / defacto 161/247 (65%) 92 (66%) 69 (64%) 0.84
Home ownership (yes) 101/246 (41%) 34 (24%) 67 (63%) <0.0001
Employment status <0.0001
Employed, full-time 31/245 (13%) 12 (9%) 19 (18%)
Employed, part-time (<20hrs/week) 17/245 (7%) 11 (8%) 6 (6%)
Unemployed 76/245 (31%) 60 (43%) 16 (15%)
Retired 121/245 (49%) 56 (40%) 65 (61%)
Education 0.95
None 7/244 (3%) 4 (3%) 3 (3%)
Primary and /or secondary school 132/244 (54%) 74 (53%) 58 (55%)
Tertiary 105/244 (43%) 61 (44%) 44 (42%)
Income (AUD$) 0.39
Under $379 per week 155/247 (63%) 88 (63%) 67 (63%)
$380–$579 per week 24/247 (10%) 14 (10%) 10 (9%)
$580–$769 per week 18/247 (7%) 9 (6%) 9 (8%)
$770–$959 per week 12/247 (5%) 9 (6%) 3 (3%)
>$960 per week 14/247 (6%) 10 (7%) 4 (4%)
Don’t know/rather not answer 24/247 (10%) 10 (7%) 14 (13%)
Co-morbidity (number) 3/247 (SD:2) 3 (SD:2) 2 (SD:2) 0.10
Cancer 33/247 (13%) 22 (16%) 11 (10%) 0.21
Diabetes 99/247 (40%) 53 (38%) 46 (43%) 0.41
Hypertension 170/247 (69%) 105 (75%) 65 (61%) 0.02
Depression 65/247 (26%) 41 (29%) 24 (22%) 0.23
Cardiovascular disease 84/247 (34%) 45 (32%) 39 (36%) 0.48
Current treatment type 0.53
Pre-dialysis 23/247 (9%) 11 (8%) 12 (11%)
Dialysis 199/247 (81%) 113 (81%) 86 (80%)
Home 71/199 (36%) 43 (38%) 28 (33%) 0.42
Community location 128/199 (64%) 70 (62%) 58 (67%)
Transplant recipient 25% (10%) 16 (11%) 9 (8%)
Mean time on dialysis 5.7 (SD:5.8) 5.8 (SD:5.4) 5.6 (SD:6.3) 0.83
Mean time since diagnosis, years 12.7 (SD:11.8) 12.0 (SD:11.6) 13.7 (SD:12.2) 0.30
Quality of life♦, EQ5D[15] 0.64 (SD:0.25) 0.59 (SD:0.23) 0.70 (SD:0.25) <0.001
Pre-dialysis 0.62 (SD:0.26) 0.57 (SD:0.23) 0.66 (SD:0.29) 0.42
Dialysis 0.64 (SD:0.24) 0.59 (SD:0.23) 0.70 (SD:0.25) 0.002
Transplant 0.66 (SD:0.26) 0.59 (SD:0.26) 0.77 (SD:0.23) 0.12
Need assistance with ADLs 150/247 (61%) 98 (70%) 52 (49%) <0.001
Family carer 102/243 (42%) 70 (50%) 32 (30%) 0.003
Essue et al. BMC Nephrology 2013, 14:5 Page 5 of 9
http://www.biomedcentral.com/1471-2369/14/5
Table 1 Participant characteristics overall and by hardship status (Continued)
Number of social encounters (per week) 0.01
0 72/247 (29%) 42 (30%) 30 (28%)
1-3 127/247 (51%) 80 (57%) 47 (44%)
4-6 23/247 (9%) 11 (8%) 12 (11%)
>6 25/247 (10%) 7 (5%) 18 (17%)
Catastrophic spending (out-of-pocket spending >10% of income) 153/216 (71%) 85 (67%) 68 (76%) 0.13
Mean out-of-pocket spending (AUD$/quarter)* 907 (SD:1070) 930 (SD:1123) 876 (SD:997) 0.18
Receiving any concessions and /or subsidies 183/247 (74%) 115 (82%) 68 (64%) 0.001
Income negatively impacted by illness 142/247 (58%) 105 (75%) 37 (35%) <0.0001
Private health insurance 91/247 (37%) 40 (29%) 51 (48%) 0.002
Able to pay AUD$2000 for something important in a week (access to financial resources) 125/247 (51%) 42 (30%) 83 (78%) <0.0001
Data are presented as either mean (SD=standard deviation) or count (%=proportion).
♦n=229, missing quality of life data for n=18.
*Difference in median spending assessed using non-parametric statistical tests.
AU$1=US$1=EU€0.73=BGP£0.62; January 2011.
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countries, the incidence of out-of-pocket costs exceeding
US$1000 in the previous year among individual partici-
pants was 21% in Australia – behind only the United
States (35%) and Switzerland (25%) [22]. The currentFigure 2 Proportion of participants reporting each indicator of hardsstudy makes an important contribution to the literature
in this area by improving our understanding of the poo-
rer economic circumstances of households affected by
chronic illness and identifying the financial stressors that
increase the likelihood of hardship in a CKD population.hip.






Age 0.97 (0.95–0.99) <0.001 0.99 (0.96–1.02) 0.32
Home ownership (yes) 0.19 (0.11–0.32) <0.0001 0.32 (0.14–0.71) 0.005
Quality of life 0.14 (0.04–0.43) <0.001 0.12 (0.02–0.56) 0.007
Number of social encounters (per week) 0.02 0.01
0 1.00 1.0
1-3 3.60 (1.34–9.69) 1.90 (0.79–4.57)
4-6 4.38 (1.70–11.25) 0.58 (0.16–2.11)
>6 2.36 (0.71–7.80) 0.31 (0.09–1.09)
Receiving concessions and subsidies for living and medical expenses 10.57 (1.47–14.74) 0.001 3.09 (1.38–6.91) 0.006
Income impacted by illness (due to early departure from work or change in employment) 5.68 (3.27– 9.86) <.0001 4.80 (2.17–10.62) 0.0001
Access to financial resources (could pay AUD$2000 in a week for something important) 0.12 (0.07–0.22) <.0001 0.24 (0.11–0.50) 0.0001
a Hosmer and Lemeshow goodness-of-fit test; : χ2: 4.48, p=0.81.
The adjusted model was built manually and included all variables associated with hardship at the level of P <0.25 in univariate analysis (shown in Table 1).
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Australia having a comprehensive social health insurance
system that is seen to be universal. Previous studies
show out-of-pocket costs for treatment can pose serious
barriers to adherence to recommended medical care
[4,10,23,24], especially for those who are socioeconomi-
cally disadvantaged. Patients with hardship were spend-
ing similar amounts out-of-pocket overall and in each
medical and health related expense category across the
stages of CKD. Patients with low means often prioritise
paying for medical care over other important expenses
[11]. The impact of large out-of-pocket costs for patients
with low financial resources can be severe. We foundFigure 3 Mean out-of-pocket costs in the previous three months for ea13% of participants reported going without meals, 11%
were unable to heat their homes, 12% increased the amount
owing on their credit cards by greater than $AUD1000 and
19% missed medical appointments or failed to fill pres-
criptions because they were short of money. While not
explored in this study, other research has shown that clini-
cians are often unaware that their patients’ are facing diffi-
culty managing out-of-pocket costs [25]. Patients can be
reluctant to discuss cost pressures with their health care
providers because of a perception that there are few viable
solutions to the problem [10,24,25]. Clinicians could play a
greater role in identifying patients at risk of hardship and
linking them into existing social welfare support programs.ch medical and health-related expense category by stage of illness.
Table 3 Summary of out-of-pocket costs by hardship status (out-of-pocket costs in the previous three months)
Out-of-pocket cost category n Minimum Maximum Mean (SE) Mean differencea Pb Median (IQR) Pc
All
Hardship 99 15 5250 876 (100) 54 0.7 655 (800) 0.2
No hardship 136 32 9460 930 (96) 540 (720)
Medical care
Hardship 100 0 6150 280 (84) 76 0.5 40 (200) 0.7
No hardship 82 0 5250 204 (74) 53 (150)
Medications
Hardship 128 20 2000 304 (27) 57 0.08 200 (280) 0.6
No hardship 100 0 1200 247 (18) 200 (195)
Transport*
Hardship 112 0 1800 268 (26) -60 0.1 200 (304) 0.2
No hardship 87 0 1200 328 (33) 240 (380)
Management and supportive care
Hardship 55 15 6430 552 (129) 94 0.6 265 (500) 0.8
No hardship 33 6 2710 458 (113) 230 (350)
AU$1=US$1=EU€0.73=BGP£0.62; January 2011.
SE: Standard error; IQR: Interquartile range.
* Medically related transport.
a Mean difference: ―x (hardship) - ―x (no hardship).
b Difference in means tested using the independent t-test.
c Difference in distribution of medians tested using the Mann Whitney U test.
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nical practice. In contrast to the published literature on
the quality of life of CKD patients [26], we found no dif-
ferences in quality of life scores across the different
stages of illness. However, patients with hardship had
lower quality of life across the three stages of CKD and
it was significantly lower for patients receiving dialysis
care. These findings highlight the inter-relationship be-
tween chronic illness, economic wellbeing and quality of
life. Maximising quality of life is an important treatment
outcome to minimise morbidity and mortality rates in
the management of CKD patients. However, maximising
quality of life is also associated with other important
economic outcomes such as maintaining employment
and independence [27]. The clinical management of
CKD should take account of these broader outcomes
which are relevant to the overall well-being of patients
and their households.
This study has limitations. We achieved a participation
rate of 63% and over-sampled patients receiving dialysis
care in a community setting. This sample is also drawn
from a predominantly low socioeconomic setting. How-
ever, comparison of the demographic and socioeconomic
characteristics of our sample with the treated incident
renal population in Australia and a national census of
patients on dialysis shows that our sample is younger,
less sick and has a higher proportion in patients still
in paid employment (Additional file 1: Table S2). We
have likely under-estimated the true economic impact ofCKD for patients who are socioeconomically disadvan-
taged. In addition, the observed non-response is likely
related to both outcomes and to hardship status, giving
a potential for bias in association. We did not sample
non-English speaking participants. The extent of hard-
ship may be even more pronounced in these groups be-
cause of inherent reasons, including their ability to
access and navigate existing social welfare supports. Fi-
nally, we measured hardship at one time point. It is
likely that patients employ different coping strategies
over time to improve their circumstances. A prospective
design would allow assessment of the change in financial
circumstances and understand better the direction of
causation. In this study, the aim was instead to describe
the lived experience of patients in which economic hard-
ship, poor health and other aspects of social disadvan-
tage co-exist. Given that our study population had been
receiving dialysis for a mean of five years and were on
average 12 years past their diagnosis, our results likely
reflect the situation of the established ‘steady state’ for
the households affected, demonstrating a need for early
interventions to assist households to better cope with
the negative economic sequelea of CKD.
Conclusion
This study found a considerable proportion of patients
face hardship and high out-of-pocket spending asso-
ciated with the care and management of CKD in Austra-
lia. This research raises important practice implications
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and supporting patients who are experiencing hardship,
particularly in settings that rely heavily on out-of-pocket
costs to fund CKD treatment, such as in the US. It also
provides a basis for further investigation of the add-
itional supports required to better assist households
affected by CKD, which would likely also be of benefit to
other chronically ill patient populations.
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